Cytotoxic activity and effect on nitric oxide production of tirucallane-type triterpenes.
Hexane extract from the bark of Amphipterygium adstringens, as well as its principal constituents, masticadienonic acid and 3alpha-hydroxymasticadienolic acid, inhibited the growth of five human cancer cell lines. Derivatives of, namely 24,25 S-dihydromasticadienonic acid and masticadienolic acid, were also evaluated. The results showed that both and had greater activity than on colon cancer cell lines. The effects of on the production of nitric oxide (NO) from both resting and lipopolysaccharide-activated macrophages were determined. It was found that and caused an increase in NO release from resting macrophages; in lipopolysaccharide-activated macrophages, only and caused an increase in NO production.
Chávez
Ibeth Oviedo
IO
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán, C. P. 04510, México, D. F., México.
Apan
Teresa Ramírez
TR
Martínez-Vázquez
Mariano
M
D027926:Anacardiaceae; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D016543:Central Nervous System Neoplasms / Q000473:pathology; D003110:Colonic Neoplasms / Q000473:pathology; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D006586:Hexanes / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000473:pathology; D008070:Lipopolysaccharides / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008519:Medicine, Traditional; D008800:Mexico / Q000208:ethnology; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism*; D010936:Plant Extracts / Q000737:chemistry / Q000302:isolation & purification; D011471:Prostatic Neoplasms / Q000473:pathology; D012235:Rhodamines / Q000494:pharmacology; D014315:Triterpenes / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D000097245:Ursolic Acid
D000972:Antineoplastic Agents, Phytogenic; D006586:Hexanes; D008070:Lipopolysaccharides; D009569:Nitric Oxide; D010936:Plant Extracts; D012235:Rhodamines; D014315:Triterpenes; D000097245:Ursolic Acid; C506844:24,25S-dihydromasticadienonic acid; C459621:masticadienolic acid; C459620:masticadienonic acid; C022027:lissamine rhodamine B